It doesn't matter if you're a computer geek or complete technophobe: If you've ever made the effort to download your blood glucose meter, you probably don't have a clue about what to do with the data once you've gotten it. That needs to change. Those of us who live with diabetes need to become more adept at analyzing our own data, to see what's working and what isn't both for our own sake and that of our time-strapped healthcare providers. .
Infopia USA's Eocene System is a diabetes management system with a data collection device that gathers data from a meter, blood pressure cuff, and a thermal scale. Readings are stored on Infopia's network and available to you and your health team. See the video on Diabetes Health TV here.
Sitagliptin (Januvia) has long been used to reduce blood sugar in people with type 2 diabetes, but a new study indicates that it can do the same for those with type 1 diabetes. Sitagliptin is a DPP-4 inhibitor; that is, it inhibits, or temporarily prevents, the enzyme DPP-4 from destroying a helpful hormone called GLP-1. GLP-1, which is released by the gut when food arrives there from the stomach, lowers blood sugar by causing the release of insulin, reducing the secretion of glucagon, and slowing stomach emptying and nutrient absorption.
Arena Pharmaceuticals and Eisai Inc. recently released results of a phase 3 clinical trial for lorcaserin, a weight-loss drug they are developing in partnership. The trial, called BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management- Diabetes Management), targeted patients with type 2 diabetes who are overweight or obese.
If you have type 1 diabetes, you know that the process of obtaining life insurance or long-term care insurance has been a long, tough road, most often leading to the dead end of declined coverage. In fact, most insurance companies have classified anyone with type 1 as an automatic decline, without any consideration of each case individually.
A new drug for type 2 diabetes started showing up in drugstores this week, according to manufacturer Santarus. The FDA-approved drug, called Cycloset, takes an distinctive -- and not well understood -- approach to reducing blood sugar levels. The pill apparently works by increasing dopamine activity in the hypothalamus, a part of the brain. Dopamine is a brain chemical that plays a big role in people's behavior, mood, and ability to sleep. Scientists theorize that glucose intolerance and insulin resistance may in part result from abnormal activity of this chemical, and that upping dopamine activity may iron out these problems.That's the theory, at least: the drug's exact workings aren't known. But it seems to do the trick.
When I was diagnosed with type 1 diabetes 23 years ago, I remember being told that having children would be a very difficult challenge. I was seven years old at the time - still a child myself - and had no interest in becoming a mom. My own mother was very distressed at this news, but I didn't pay it any mind. I had other things to focus on: trees to climb, bikes to ride, and friends to play with.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.